| 1 |
Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models
|
期刊论文 |
Huihui Chong;Jing Xue;Yuanmei Zhu;Zhe Cong;Ting Chen;Yan Guo;Qiang Wei;Yusen Zhou;Chuan Qin;Yuxian He |
| 2 |
Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
|
期刊论文 |
Danwei Yu;Yang Su;Xiaohui Ding;Yuanmei Zhu;Bo Qin;Huihui Chong;Sheng Cui;Yuxian He |
| 3 |
Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity
|
期刊论文 |
Yuanmei Zhu;Huihui Chong;Danwei Yu;Yan Guo;Yusen Zhou;Yuxian He |
| 4 |
一种冠状病毒膜融合抑制剂及其药物用途
|
专利 |
何玉先;朱园美;种辉辉;周述靓 |
| 5 |
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
|
期刊论文 |
Huihui Chong;Jing Xue;Shengwen Xiong;Zhe Cong;Xiaohui Ding;Yuanmei Zhu;Zixuan Liu;Ting Chen;Yifan Feng;Lei He;Yan Guo;Qiang Wei;Yusen Zhou;Chuan Qin;Yuxian He |
| 6 |
Structural and functional characterization of HIV-1 cell fusion inhibitor T20
|
期刊论文 |
Xiujuan Zhang;Xiaohui Ding;Yuanmei Zhu;Huihui Chong;Sheng Cui;Jinsheng He;Xinquan Wang;Yuxian He |
| 7 |
Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor
|
期刊论文 |
Danwei Yu;Xiaohui Ding;Zixuan Liu;Xiyuan Wu;Yuanmei Zhu;Huanmian Wei;Huihui Chong;Sheng Cui;Yuxian He |
| 8 |
强效抑制HIV的脂肽、其衍生物、其药物组合物及其用途
|
专利 |
何玉先;种辉辉;朱园美 |
| 9 |
一种广谱冠状病毒膜融合抑制剂及其药物用途
|
专利 |
何玉先;朱园美;于丹葳;周述靓 |
| 10 |
The Tryptophan-Rich Motif of HIV-1 Gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of Gp41 and Its Inhibitors
|
期刊论文 |
Yuanmei Zhu;Xiaohui Ding;Danwei Yu;Huihui Chong;Yuxian He |
| 11 |
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
|
期刊论文 |
Danwei Yu;Yuanmei Zhu;Tao Jiao;Tong Wu;Xia Xiao;Bo Qin;Huihui Chong;Xiaobo Lei;Lili Ren;Sheng Cui;Jianwei Wang;Yuxian He |
| 12 |
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors. Viruses
|
期刊论文 |
Xiuzhu Geng;Zixuan Liu;Danwei Yu;Bo Qin;Yuanmei Zhu;Sheng Cui;Huihui Chong;Yuxian He |
| 13 |
Defective HIV-1 envelope gene promotes the evolution of the infectious strain through recombination in vitro
|
期刊论文 |
Huamian Wei;Danwei Yu;Xiuzhu Geng;Yuxian He |
| 14 |
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
|
期刊论文 |
Yuanmei Zhu;Danwei Yu;Hongxia Yan;Huihui Chong;Yuxian He |
| 15 |
A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of HIV-1, HIV-2, and Simian Immunodeficiency Virus
|
期刊论文 |
Xiaoran Tang;Hongliang Jin;Yue Chen;Li Li;Yuanmei Zhu;Huihui Chong;Yuxian He |
| 16 |
Enfuvirtide (T20)-based Lipopeptide Is a More Potent HIV-1 Cell Fusion Inhibitor: Implication for Viral Entry and Inhibition
|
期刊论文 |
Xiaohui Ding;Xiujuan Zhang;Huihui Chong;Yuanmei Zhu;Huamian Wei;Xiyuan Wu;Jinsheng He;Xinquan Wang;Yuxian He |
| 17 |
SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
|
期刊论文 |
Yuanmei Zhu;Danwei Yu;Yue Hu;Tong Wu;Huihui Chong;Yuxian He |
| 18 |
A helical short-peptide fusion inhibitor with highly potent activity against HIV-1, HIV-2 and simian immunodeficiency virus
|
期刊论文 |
Shengwen Xiong;Pedro Borrego;Xiaohui Ding;Yuanmei Zhu;Andreia Martins;Huihui Chong;Nuno Taveira;Yuxian He |
| 19 |
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy
|
期刊论文 |
Yue Chen;Hongliang Jin;Xiaoran Tang;Li Li;Xiuzhu Geng;Yuanmei Zhu;Huihui Chong;Yuxian He |
| 20 |
广谱抑制HIV的脂肽、其衍生物、其药物组合物及其用途
|
专利 |
何玉先;种辉辉;丁晓慧;熊胜文;朱园美 |
| 21 |
Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques
|
期刊论文 |
Huihui Chong;Jing Xue;Yuanmei Zhu;Zhe Cong;Ting Chen;Qiang Wei;Chuan Qin;Yuxian He |
| 22 |
Identification of a Novel HIV-1-Neutralizing Antibody from a CRF07_BC-Infected Chinese Donor
|
期刊论文 |
Sun Y;Qiao Y;Man L;Zhu Y;Chong H;He Y |
| 23 |
Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor
|
期刊论文 |
Xiyuan Wu;Zixuan Liu;Xiaohui Ding;Danwei Yu;Huamian Wei;Bo Qin;Yuanmei Zhu;Huihui Chong;Sheng Cui;Yuxian He |
| 24 |
Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
|
期刊论文 |
Yuanmei Zhu;Xiujuan Zhang;Xiaohui Ding;Huihui Chong;Sheng Cui;Jinsheng He;Xinquan Wang;Yuxian He |
| 25 |
Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
|
期刊论文 |
Xiujuan Zhang;Yuanmei Zhu;Hao Hu;Senyan Zhang;Pengfei Wang;Huihui Chong;Jinsheng He;Xinquan Wang;Yuxian He |
| 26 |
Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
|
期刊论文 |
Huihui Chong;Yuanmei Zhu;Danwei Yu;Yuxian He |
| 27 |
Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
|
期刊论文 |
Hongliang Jin;Xiaoran Tang;Li Li;Yue Chen;Yuanmei Zhu;Huihui Chong;Yuxian He |
| 28 |
广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用
|
专利 |
何玉先;朱园美;于丹葳;种辉辉 |
| 29 |
一种广谱冠状病毒膜融合抑制剂及其药物用途
|
专利 |
何玉先;朱园美;种辉辉;周述靓 |
| 30 |
Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide
|
期刊论文 |
Jing Xue;Huihui Chong;Yuanmei Zhu;Jingjing Zhang;Ling Tong;Jiahan Lu;Ting Chen;Zhe Cong;Qiang Wei;Yuxian He |
| 31 |
Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
|
期刊论文 |
Danwei Yu;Yuanmei Zhu;Hongxia Yan;Tong Wu;Huihui Chong;Yuxian He |
